Berlex Foundation Seeks Workshop Applicants
DUMONT, NJ--The Berlex On-cology Foundation is seeking applicants for two workshops: Epidemiology and Clinical Trial Design, to be held August 23-29, 1996, in Brewster, Mass, and The Clinical Pharmacology of Anticancer Drugs, which will take place October 4-8, 1996, in Leesburg, Va.
DUMONT, NJ--The Berlex On-cology Foundation is seeking applicantsfor two workshops: Epidemiology and Clinical Trial Design, tobe held August 23-29, 1996, in Brewster, Mass, and The ClinicalPharmacology of Anticancer Drugs, which will take place October4-8, 1996, in Leesburg, Va.
Aimed at young investigators interested in cancer research, theinteractive workshops offer ample opportunity for one-on-one interfacingwith the faculty, as well as peer-to-peer networking.
The awards cover travel expenses, lodging, meals, course syllabus,and textbooks. The application deadlines are May 30, 1996, forthe epidemiology workshop, and June 30, 1996, for the anticancerdrugs course. Twenty scholars will be selected for each program.
All applicants must be currently enrolled in an accredited oncologytraining program and should possess a demonstrated interest incancer research. Applicants must supply a current curriculum vitae,letter of recommendation from the department chairman, and a one-pageletter describing the applicant's purpose in attending the program.
For more information, contact Svetlana Lisanti, Berlex OncologyFoundation, 80 W. Madison Ave., Dumont, NJ 07628, or telephone201-385-0006.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F9addaac21d809a7b642a567b0a704cbb15d87ac5-2966x1684.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.")
